Lilly Pulitzer’s treasured Sunshine Sale is back with splurge-worthy discounts and new styles perfect for the winter or ...
Effective electrical wall outlets are an essential part of any home, but their low profile means that they're often overlooked, leading to potential safety hazards. They also don't last forever.
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.
Pulitzer Prize-winning cartoonist Darrin Bell has been arrested on suspicion of possessing child sexual abuse videos, including AI-generated material. The Sacramento County Sheriff's Office said ...
Shares of Eli Lilly (NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for the fourth quarter of 2024. The pharmaceutical giant expects only $13.5 ...
Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...
Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema ...
Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.
Senior equity analysts at StockNews.com upgraded Eli Lilly (LLY, Financial) stock from 'hold' to 'buy' as its stock has shifted positively. Analysts say the upgrade is a sign of increased ...
A Pulitzer Prize-winning cartoonist was arrested Wednesday and accused of possessing dozens of child sex abuse videos, police said. A search warrant was served Wednesday at the home of Darrin Bell, 49 ...
Eli Lilly has been riding the weight-loss drug wave. The company's weight-loss drugs have been shown to be more effective than rival Ozempic. The stock currently trades at an attractive valuation.